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Detection of methylated free-circulating DNA (mfcDNA) for hyperplastic polyposis 1 (HPP1) in blood is correlated with a poor
prognosis for patients with metastatic colorectal cancers (mCRC). Here, we analyzed the plasma levels of HPP1mfcDNA in mCRC
patients treated with a combination therapy containing a fluoropyrimidine, oxaliplatin and bevacizumab to test whether HPP1
mfcDNA is a suitable prognostic and response biomarker. From 467 patients of the prospective clinical study AIO-KRK-0207,
mfcDNA was isolated from plasma samples at different time points and bisulfite-treated mfcDNA was quantified using methylation
specific PCR. About 337 of 467 patients had detectable levels for HPP1mfcDNA before start of treatment. The detection was
significantly correlated with poorer overall survival (OS) (HR51.86; 95%CI 1.37–2.53). About 2–3 weeks after the first
administration of combination chemotherapy, HPP1mfcDNA was reduced to non-detectable levels in 167 of 337 patients.
These patients showed a better OS compared with patients with continued detection of HPP1mfcDNA (HR HPP1(sample 1: pos/
sample 2: neg) vs. HPP1(neg/neg)51.41; 95%CI 1.00–2.01, HPP1(neg,pos/pos) vs. HPP1(neg/neg)52.60; 95%CI 1.86–3.64).
Receiver operating characteristic analysis demonstrated that HPP1mfcDNA discriminates well between patients who do (not)
respond to therapy according to the radiological staging after 12 or 24 weeks (AUC50.77 or 0.71, respectively). Detection of
HPP1mfcDNA can be used as a prognostic marker and an early marker for response (as early as 3–4 weeks after start of treatment
compared with radiological staging after 12 or 24 weeks) to identify patients who will likely benefit from a combination chemo-
therapy with bevacizumab.
Introduction
The introduction of chemotherapeutic combination regimen
including fluoropyrimidines, oxaliplatin and irinotecan, as
well as monoclonal antibodies (like cetuximab, panitumumab
and bevacizumab) to first- and further line treatment regimen
have improved the overall survival of patients with mCRC.
However, long-term survival rates of patients with mCRC
are still low, with only few patients being eventually cured.1–4
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Currently, only the pathohistological tumor staging (TNM) is
used as prognostic parameter in the clinic. Analysis of the
RAS mutational status is the only predictive marker for the
treatment of CRC patients with the anti-EGFR antibodies
cetuximab and panitumumab.1–4 For this reason, additional
tissue or blood biomarkers are urgently needed to improve
prediction and to guide therapies.
So far, several tissue-based biomarkers with the potential
to be used in the clinic have been described to classify sub-
types of colorectal tumors, for example, microsatellite insta-
bility, CpG island methylator phenotype (CIMP), mutations
of DNA repair genes5 and RAS.1 However, the detection of
these markers depends on the analysis of a biopsy or tumor
tissue after resection. In addition, because of intratumoral
heterogeneity as well as heterogeneity between metastases,
the analysis of one biopsy might not necessarily represent the
whole tumor burden of a given patient.6 However, analysis of
multiple biopsies is not feasible in the clinical routine. Potent
blood-derived biomarkers might overcome this problem.7
CEA and CA19-9 were the first blood-based biomarkers for
colorectal cancer. CEA has been described as an independent
prognostic tumor marker for the overall survival of patients
with curatively resectable or metastasized CRC.8–13 New studies
revealed that high CEA serum levels at the beginning of a
combination therapy including bevacizumab are correlated
with a poor prognosis.14 Furthermore, increasing CEA levels
during a treatment with oxaliplatin-based chemotherapy with
bevacizumab indicate tumor progression.15 Nevertheless, CEA
is not an established response marker. Instead, response evalua-
tion criteria in solid tumors (RECIST-1) are commonly used to
define the degree of tumor response to chemotherapies.16
Treatment of patients with tumors should result in tumor
shrinkage that can be monitored using radiological screening.17
Tumor cells of primary tumors and metastases are constantly
turned over with their DNA being released into circulation. Free-
circulating tumor DNA can be isolated and analyzed for muta-
tions and methylation patterns derived from tumor cells.7 In con-
trast to repeated biopsies, repeated sampling and analysis of
blood-derived markers is feasible. Next to the detection of muta-
tions in proto-oncogenes and tumor suppressor genes in free-
circulating DNA,18–20 detection of methylated, free-circulating
tumor DNA has been intensively studied in recent years.21–24
Increased methylation of regulatory gene sequences, so called
CpG islands in the promoter region of genes, is a hallmark of
tumor cells25–27 and can be used to differentiate normal and
tumor cells.28,29 It has been shown that the detection of gene
methylation for individual genes in blood samples, like
CDKN2A, MYOD1, ID4 and HPP1,30–33 as well as the methyla-
tion of a panel of genes was correlated with a poor prognosis of
patients with colorectal carcinomas at late stages.34,35
The gene HPP1 (hyperplastic polyposis 1/transmembrane
protein containing epidermal growth factor and follistatin
domains) encodes a transmembrane protein and is frequently
methylated in colorectal tumors.36,37 Previously, HPP1 has
been shown to activate STAT1 signaling for its function as a
tumor suppressor, however, Hpp1 mutant mice did not show
an increased tumor burden.38,39 We have demonstrated that
detection of methylated free-circulating HPP1 DNA in blood
samples is a prognostic factor for patients with mCRC.33,40–42
In the prospective study AIO-KRK-0207, different strate-
gies for maintenance treatments were examined, following a
24 week combination chemotherapy with a fluoropyrimidine
(5-FU or capecitabine), oxaliplatin plus bevacizumab.43 Blood
samples were collected during the combination chemotherapy
for translational projects. Here, the levels of HPP1 mfcDNA
and CEA in blood samples before and 2–3 weeks after the
start of the chemotherapy were determined and correlated
with OS and response (radiological staging after 12 and
24 weeks, respectively), to evaluate whether HPP1 mfcDNA
and CEA are suitable markers for prognosis and early
response to therapy.
Material and Methods
Study design and patients
The clinical study AIO-KRK-0207 (NCT00973609; https://
clinicaltrials.gov/ct2/show/record/NCT00973609) is a randomized
three arm phase III trial with different maintenance strategies after
a 24-weeks combination chemotherapy, consisting of a treatment
with a fluoropyrimidine, oxaliplatin and bevacizumab. Investi-
gators assessed tumor response by CT or MRI scans at weeks
12 and 24 according to RECIST version 1.0 (see Ref. 43 for details
regarding the protocols). Blood samples were drawn prior to the
treatment start (Day 1; “BS1”) and after 15 to 22 days (corre-
sponding to the first administration of FOLFOX or CAPOX
regime, respectively; “BS2”). Plasma was used to quantify HPP1
mfcDNA; CEA was measured as a reference using serum. Charac-
teristics of the patient cohort are shown in Table 1. Out of the 825
patients that were included in the clinical study AIO-KRK-0207,
What’s new?
Tumor cells of primary tumors and metastases are constantly turned over with their DNA being released into blood circulation.
Here the authors quantified circulating DNA of the hyperplastic polyposis 1 (HPP1) gene, which is frequently methylated in
colorectal tumors, in a prospective clinical study of combination chemotherapy in patients with metastatic colorectal cancer.
They confirmed their previous finding that HPP1 methylated free-circulating DNA (mfcDNA) is a prognostic marker for
progression-free and overall survival in these patients. In addition, HPP1 mfcDNA served as a marker differentiating between
chemotherapy responders and non-responders, underscoring the usefulness of DNA-based biomarkers in cancer treatment.
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blood samples were available for 467 patients. The 467 patients
did not differ from the 358 patients that have been excluded from
this study due to missing blood samples with respect to several
variables (Supporting Information Table 1).
Blood samples
Blood samples underwent standardized pre analytical proce-
dures. Serum: Blood was drawn using serum monovettes
(Sarstedt, N€urnbrecht, Germany), incubated at room temper-
ature for 60 min and centrifuged for 10 min at 2,000g. The
supernatant was decanted and used for CEA measurements.
Plasma: Blood was drawn using EDTA monovettes (Sarstedt)
and centrifuged for 10 min at 2,000g. The supernatant was
transferred to a new tube and used for DNA isolation and
bisulfite conversion.
DNA isolation and bisulfite conversion
The frozen plasma samples were thawed at room temperature
and homogenized by smoothly flicking the tube. Genomic
DNA from 200 mL of each plasma sample was isolated using
the High Pure Viral Nucleic Acid Kit (Roche Applied Sci-
ence, Mannheim, Germany) according to the manufacturer’s
instructions and eluted in 50 mL of Elution Buffer. Sodium
bisulfite conversion of DNA was performed using the EZ DNA
Methylation-Gold Kit (Zymo Research, Freiburg, Germany)
according to the manufacturer’s protocol.
Analysis of DNA methylation
Bisulfite-treated DNA was analyzed by a fluorescence-based,
real-time PCR assay, described previously as Methy-Light.44
Dispersed Alu repeats were used to control for DNA
amplification and to normalize for input DNA. Primer and
probe sequences for HPP1 and Alu have been described
previously.33 PCRs were performed in a reaction volume of
20 lL containing 13 PCR buffer (Qiagen, Hilden, Germany),
4 mmol/L MgCl2, 250 lmol/L desoxynucleotide triphosphate
mixture, 2 lL bisulfite-treated DNA, 0.05 units/lL Taq DNA
polymerase (HotStar Taq, Qiagen) along with HPP1 specific
primers and probe as described previously33 (see also
Supporting Information Fig. 1). PCRs were conducted in a
Mastercycler ep realplex4 (Eppendorf, Hamburg, Germany)
using the following conditions: 958C for 900 sec followed by
50 cycles of 958C for 30 sec, 608C for 120 sec and 848C for
20 sec. The specificity of all reactions for methylated DNA
was confirmed by separately amplifying completely methylated
and unmethylated human control DNA (Chemicon, Temecula,
CA) with each set of primers and probes. Samples were
analyzed in triplicates and the average amount of HPP1 or Alu,
respectively, was used for the calculations. The percentage of
fully methylated reference (PMR) at a specific locus was calcu-
lated as described previously44 by dividing the gene/Alu ratio of
a sample by the gene/Alu ratio of fully methylated, bisulfite-
treated DNA (CpGenomeTM Universal Methylated DNA,
Millipore, Billerica, MA). A gene was considered methylated if
Table 1. Patient characteristics
N (%)
All patients 467 (100)
Age
<70 years 310 (66.4)
70 years 157 (33.6)
Gender
Female 168 (36.0)
Male 299 (64.0)
ECOG
0 258 (55.2)
112 193 (41.3)
Unknown 16 (3.4)
Primary tumor site
Colon 298 (63.8)
Rectum 169 (36.2)
Number of metastatic sites
1 198 (42.4)
>1 267 (57.2)
Unknown 2 (0.4)
Synchronous/metachronous metastasis
Synchronous 391 (83.7)
Metachronous 76 (16.3)
Induction therapy1
CAPOX 19 (4.1)
FOLFOX4 145 (31.0)
FOLFOX4MOD 107 (22.9)
FOLFOX4SIMPLE 46 (9.9)
FOLFOX6 84 (18.0)
FOLFOX7MOD 5 (1.1)
XELOX 59 (12.6)
Unknown 2 (0.4)
Radiological staging (12 weeks)
CR 3 (0.6)
PR 210 (45.0)
SD 175 (37.5)
PD 32 (6.9)
ND 47 (10.1)
Radiological staging (24 weeks)
CR 10 (2.1)
PR 222 (47.5)
SD 140 (30.0)
PD 79 (16.9)
ND 16 (3.4)
Blood samples were available for 467 patients.
1All patients received bevacizumab; ND not determined.
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the percentage of the fully methylated reference value was
greater than 0.
Quantification of CEA
CEA was quantified using a micro particle immuno enzymometric
assay (AxSYM, Abbott Laboratories, Chicago, IL).
Statistical analysis
The event time data on OS and PFS were analyzed by
Kaplan–Meier estimates, log rank test, and the Cox propor-
tional hazards model. We defined the time to event starting
at the date of the first biomarker measurement. These analy-
ses also were performed in the subgroup of randomized
patients stratified for treatment arms. Stratification allows
taking into account non-proportional treatment specific
baseline hazards by studying effects of factors across the
treatment arms (Supporting Information Tables 3 and 4). In
addition, multivariate Cox regression models including estab-
lished prognostic factors together with CEA and HPP1 were
analyzed and compared by means of the Akaike information
criterion (AIC). In the sense of the AIC a model is better
with respect to the comparator if the AIC of the comparator
is larger (Supporting Information Table 5). Small AICs indi-
cate better models. Robustness of the preferred final model
was investigated in 200 bootstrap samples. How biomarker
values or changes are able to discriminate response to thera-
py was analyzed using receiver-operator curves (ROC) curves
and area under the curves (AUC) as described previously.45
The analyses were performed with SAS V9.4 and R Version
2.13.2 using the packages survival [Version 2.36-9, Terry
Therneau, 2011] and ROCR [Version 1.0-4, Tobias Sing,
Oliver Sander, Niko Beerenwinkel, Thomas Lengauer, 2009].
Results
Correlation of the HPP1 methylation status
with overall survival
Blood samples were drawn at defined time points before treat-
ment (“BS1”) and after one administration of the combination
chemotherapy treatment (Day 15 or 22; “BS2”). Radiological
staging of the tumor was performed 12 (“RS1”) and 24 weeks
(“RS2”) after the start of the combination chemotherapy as
indicated by arrows (Fig. 1a). Out of the 825 patients that were
eligible to participate in the study AIO-KRK-0207 and received
combination chemotherapy, blood samples BS1 and BS2 were
available for 467 patients (Fig. 1b and Table 1).
Of the 467 mCRC patients, 337 (72%) had detectable HPP1
mfcDNA levels before therapy. Patients with detectable levels of
HPP1mfcDNA in the first blood sample had a lower overall sur-
vival compared with patients with non-detectable levels of HPP1
mfcDNA (HR5 1.86; 95% CI 1.37–2.53) (Fig. 2a, Table 2). Like-
wise, patients with CEA levels above the median of 56.4 ng/mL
(“CEA high”) in the first blood sample had a lower overall
survival compared with patients with CEA levels below the
median (“CEA low”) (HR5 1.82; 95% CI 1.41–2.35) (Fig. 2b,
Table 2). In the second blood sample, the respective hazard ratio
was higher for HPP1 mfcDNA compared with CEA (“HPP1
BS2”: HR5 2.13; 95% CI 1.65–2.74 vs. “CEA BS2”: HR5 1.75;
95% CI 1.36–2.25) (Figs. 2c and 2d, Table 2).
Treatment of the patients resulted in a statistically signifi-
cant change of HPP1 mfcDNA and CEA levels in the second
blood sample compared with the first one (p< 0.0001 for both
variables, Supporting Information Fig. 2). After the first admin-
istration of combination chemotherapy, HPP1 mfcDNA levels
were reduced to non-detectable levels in 167 out of 337
patients. The 167 patients with non-detectable HPP1 mfcDNA
levels in the second blood sample (“pos/neg”) showed a better
OS compared with the 176 patients showing detectable HPP1
mfcDNA levels in the second blood sample (“neg,pos/pos,”
including 6 patients with nondetectable levels in the first and
detectable levels in the second sample) and a lower OS com-
pared with patients with nondetectable HPP1 mfcDNA in both
samples (HR “pos/neg” vs. “neg/neg”5 1.41; 95% CI 1.00–2.01,
HR “pos/pos” vs. “neg/neg”5 2.60; 95% CI 1.86–3.64) (Table
2). In contrast, only 34 (of 234) patients switched from CEA
levels above the cut-off value (“CEA BS1,” “high”) to CEA lev-
els below the cut-off value (“CEA BS1/BS2,” “high/low”). The
median overall survival of these patients (“CEA high/low”) was
26.5 months compared with 19.5 months of the 207 patients
that had CEA levels above the cut-off value after treatment
(“CEA low,high/high,” including 7 patients switching from
CEA low to CEA high) (Fig. 1f, Table 2). These data indicate
that HPP1 mfcDNA and CEA levels in the first and the second
blood sample are prognostic markers for OS in the univariate
analysis. In addition, non-detectable HPP1 mfcDNA levels in
the second blood sample of patients with initially detectable
HPP1 mfcDNA levels might indicate a response to therapy.
For progression-free survival respective results are shown in
Supporting Information Table 2. The different treatment
arms had neither an effect on OS nor PFS, since the hazard
ratios after stratification are comparable to the hazard ratios
without stratification (compare Table 2 and Supporting
Information Table 3 for OS; Supporting Information Table 2
and Supporting Information Table 4 for PFS; see also Supporting
Information Fig. 3).
Different Cox models were calculated and compared by
the Akaike information criterion (AIC) to find a suitable Cox
model that includes established clinical parameters, like the
mutational status, grading, ECOG, and tumor load (Support-
ing Information Table 5). These clinical parameters were ana-
lyzed either alone or in combination with the HPP1 mfcDNA
and/or CEA levels in blood sample 1 (BS1) or 2 (BS2) as
well as the change of HPP1 mfcDNA or CEA levels between
BS1 and BS2 (“change”). Interactions between HPP1 and
CEA were investigated but did not improve any of the
models. Since the mutational status of RAS and BRAF was
only available for 85% of the patients, we also calculated the
AIC without the mutational status to show that results in
principle do not differ for a greater number of cases. It is
important to note, however, that AIC values can directly be
compared only for analyses within the same group of cases
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and events. Comparison of the models for OS including
mutational status, grading, ECOG, and tumor load yielded an
AIC of 1,913 for the model including only these clinical vari-
ables and AICs ranging from 1,891 to 1,905 for models
including additionally CEA and HPP1. Thus, all models
including also CEA and/or HPP1 were better with respect to
AIC, the best models being clinical variables together with
HPP1 BS2 and CEA BS2 or HPP1 change and CEA change,
respectively (AIC5 1,891, Supporting Information Table 5).
However, models including only HPP1 BS2 or HPP1 change
were nearly as good (AIC5 1,892). Of these “best” models
based on the AIC calculation, the least complex one includ-
ing clinical parameters and HPP1 mfcDNA levels at BS2 is
shown (Table 3). According to this model, HPP1 mfcDNA
levels in the second blood sample represent an independent
prognostic factor for OS next to the BRAF or RAS mutation-
al status, grading, ECOG and the number of metastatic sites,
respectively (“HPP1 BS2”: HR5 2.08; 95% CI 1.31–1.53,
Table 3). This result for HPP1 was confirmed in a bootstrap
analysis: The average hazard ratio for HPP1 mfcDNA in
BS2 in 200 bootstrap samples was 2.16 (range 1.36–3.58,
p< 0.05 for 199/200 samples). Comparison of the models for
Figure 1. Schematic diagram of the combination chemotherapy and CONSORT diagram. (a) The combination chemotherapy of the prospective
study AIO-KRK-0207 lasted 24 weeks. Blood was drawn before the start (“BS1”) and after one administration (“BS2”) of the combination
chemotherapy. Radiological staging was performed after 12 (“RS1”) and 24 weeks (“RS2”). (b) 825 mCRC patients were eligible to participate
in the study AIO-KRK-0207 and were treated with the combination chemotherapy. Blood samples 1 (BS1) and 2 (BS2) were available for 467
patients and were analyzed in this study. This part is highlighted by a gray box.
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Figure 2. Kaplan-Meier plots showing overall survival. mCRC patients with undetectable/detectable HPP1 mfcDNA levels were classified as
“neg” or “pos,” respectively. Patients with CEA levels below/above the cut-off value were classified as “low” or “high,” respectively. (a) Overall
survival is shown for all 467 mCRC patients according to the levels of HPP1 mfcDNA in the first blood sample (BS1) (b) Kaplan–Meier plot based
on the CEA level in BS1. (c) and (d) The corresponding Kaplan–Meier plots based on the levels of HPP1 mfcDNA or CEA levels in the second
blood sample (BS2). (e) Kaplan–Meier plot showing the combined information regarding the HPP1 mfcDNA levels before and after the first
administration of treatment (HPP1 BS1/BS2). (f) Kaplan–Meier plot based on the combined information of CEA serum levels before and after the
first administration of treatment (CEA BS1/BS2).
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PFS yielded similar results withHPP1mfcDNA levels as an inde-
pendent prognostic factor (Supporting Information Table 6).
These data indicate that HPP1 mfcDNA levels in the first and
the second blood sample are independent prognostic markers of
clinical variables and CEA. In comparison, CEA levels in the first
and second blood sample are independent prognostic markers of
clinical variables, but only CEA in the first blood sample is also
independent ofHPP1 levels.
Table 2. Median overall survival (OS) and hazard ratios were calculated for various clinical parameters, HPP1 mfcDNA or CEA levels
Parameter Value Events/cases
Median OS
[months] CI p HR HRCI
Gender Female 93/168 21.9 (17.9–28.3) 0.0657 .
Male 153/299 28.2 (23.4–32.9) 0.79 (0.61–1.02)
Age <70 166/310 27.0 (22.8–30.2) 0.9143 .
70 80/157 24.9 (20.5–30.3) 0.99 (0.75–1.29)
ECOG 0 127/258 29.5 (25.3–34.6) 0.0002 .
112 118/193 19.7 (16.7–26.7) 1.61 (1.25–2.07)
Site Colon 164/298 23.4 (20.7–27.0) 0.0564 .
Rectum 82/169 30.0 (26.5–35.2) 0.77 (0.59–1.01)
Grading 112 141/312 30.2 (27.0–34.6) <0.0001 .
314 81/124 16.7 (14.9–22.3) 2.02 (1.53–2.65)
Metastasis metachron 35/76 31.3 (27.0– .) 0.0332 .
synchron 211/391 24.2 (20.9–28.2) 1.47 (1.03–2.11)
No. of metastatic sites 1 90/198 29.5 (24.9–36.2) 0.0086 1.41 (1.09–1.84)
>1 155/267 23.4 (19.5–28.2) .
Mutation Wild type 75/160 30.1 (26.2–38.5) 0.0001 .
NRAS/KRAS 115/205 24.2 (20.0–29.5) 1.33 (0.99–1.78)
BRAF 20/33 10.7 (9.8– .) 2.84 (1.72–4.66)
HPP1 BS1 neg. 53/130 35.2 (29.5– .) <0.0001 .
pos. 193/337 21.9 (19.5–25.9) 1.86 (1.37–2.53)
HPP1 BS2 neg. 134/291 30.2 (28.2–35.2) <0.0001 .
pos. 112/176 16.6 (14.9–20.2) 2.13 (1.65–2.74)
HPP1 BS1/BS2 neg./neg. 51/124 35.2 (30.0– .) <0.0001 .
pos./neg. 83/167 28.2 (23.9–33.9) 1.41 (1.00–2.01)
neg.,pos./pos. 112/176 16.6 (14.9–20.2) 2.60 (1.86–3.64)
CEA BS1 Low 102/233 33.4 (28.7–37.5) <0.0001 .
High 144/234 19.7 (17.3–24.4) 1.82 (1.41–2.35)
CEA BS2 Low 117/260 31.3 (28.3–35.5) <0.0001 .
High 129/207 19.5 (17.1–23.6) 1.75 (1.36–2.25)
CEA BS1/BS2 Low/low 98/226 33.4 (28.8–39.1) <0.0001 .
High/low 19/34 26.5 (19.7– .) 1.46 (0.89–2.39)
Low,high/high 129/207 19.5 (17.1–23.6) 1.84 (1.41–2.40)
Rad Staging 12 weeks CR1 PR1SD 199/388 28.3 (25.3–31.3) <0.0001 .
PD 27/32 10.1 (6.1–13.4) 6.91 (4.52–10.6)
Rad Staging 24 weeks CR1 PR1SD 174/372 30.1 (28.2–33.7) <0.0001 .
PD 61/79 11.5 (10.0–13.4) 4.57 (3.38–6.18)
Patients were grouped according to the levels of HPP1 mfcDNA in the first (BS1) or the second blood sample (BS2) into the categories “HPP1 detectable”
(pos.) or “HPP1 non-detectable” (neg.). Similarly, patients with CEA levels below/above the cut-off CEA level were defined as “CEA low” or “CEA high,”
respectively. For the combined analysis of HPP1 (and CEA) levels in BS1 and BS2, the groups “neg./pos.” (“low/high”) and “pos./pos.” (“high/high”)
were combined to generate the group “neg.,pos./pos”(“low,high/high”), since the group “neg./pos.” was small and clinically not relevant. The number
of events (deaths) and cases are listed. For each parameter the median OS was calculated. p values indicate if the median OS is statistically significant
different between matching values. Hazard ratios (HR) and the 95% confidence interval (HRCI) indicate the risk associated with a given parameter. The
mean OS was 27.2 months for the patient cohort, the median OS was 25.9 months (95% CI: 22.6–29.9).
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HPP1 mfcDNA is a response marker
About 12 and 24 weeks after the start of treatment, radiograph-
ic evaluation based on RECIST criteria was done. Patients
showing a complete remission (CR), partial remission (PR) or
stable disease (SD) were classified as “responders,” whereas
patients who showed a progressive disease (PD) were defined
as “non-responders.” According to the staging, 388 (12 weeks,
RS1) and 372 patients (24 weeks, RS2), respectively, responded
to the combination chemotherapy (Table 1). To test the suit-
ability of HPP1 mfcDNA as a marker for response, we per-
formed an ROC analysis using HPP1 mfcDNA levels in the
second blood sample to discriminate between responders (CR,
PR, SD) and non-responders (PD) according to the results of
the radiological staging after 12 and 24 weeks (Table 1). The
area under the curve (AUC) was 0.77 (radiological staging after
12 weeks) and 0.71 (24 weeks), respectively (Figs. 3a and 3b).
The negative predictive value (NPV) of HPP1 mfcDNA in BS2
was 97.7 (95.1–99.2) at RS1 and 94.4 (90.9–96.8) at RS2. In
contrast, CEA serum levels in the second blood sample did not
discriminate between these two groups of mCRC patients (12
weeks: AUC5 0.49; 24 weeks: AUC5 0.52) (Figs. 3c and 3d).
According to these data, HPP1 mfcDNA levels after the first
administration of the combination chemotherapy can be used
as a marker for response to identify CRC patients that go into
remission or show a stable tumor size. Moreover, information
regarding the HPP1 mfcDNA levels was available 2–3 weeks
after the start of the treatment, whereas the radiological staging
took place after 12 and 24 weeks, respectively.
Discussion
Detection of free-circulating tumor DNA in blood samples
represents a minimally invasive approach to biologically
represent the tumor of a patient and offers the chance to
monitor the response to treatment by measuring the levels of
fcDNA throughout the administration of a therapy.7,46,47
We have demonstrated in retrospective studies that detec-
tion of methylated free-circulating HPP1 DNA is a prognostic
factor for CRC patients UICC stage IV.33,40–42 The results of
this prospective study utilizing a homogenously treated cohort
of mCRC patients confirmed our previous results: Detection of
HPP1 mfcDNA is an independent prognostic factor for lower
overall survival. Furthermore, a reduction of HPP1 mfcDNA to
non-detectable levels after the first administration of treatment
was correlated with reduced risk of progression compared with
patients who still had detectable HPP1mfcDNA levels. In addi-
tion, the level of HPP1 mfcDNA after the first administration
of treatment was able to discriminate between patients with a
“response or stable” (CR, PR, SD) or a “progressive” (PD)
course of disease.
The results of this study show that CEA serum levels have
a prognostic value. In contrast to CEA, detection of HPP1
mfcDNA in the second plasma sample has the additional
advantage of being a marker for response. Whereas CEA is
not able to distinguish between mCRC patients with a
response or stable versus a progressive course of disease,
HPP1 mfcDNA offers the possibility to identify patients who
benefit from the therapy. Apart from patients that respond to
the treatment with a reduction of HPP1 mfcDNA to non-
detectable levels, it is also important to identify patients who
do not respond to a given therapy. This information offers
the opportunity to identify progressors earlier and to potential-
ly switch these patients to a different treatment regimen. We
have not intended in our study to give any advice in terms of
which alternative therapy should be used for patients progress-
ing during induction therapy. This question remains open and
needs to be answered by future studies. Taken together, HPP1
mfcDNA has the potential to monitor response to therapy at an
earlier time point than the radiological imaging.
To our knowledge, this is the first report demonstrating the
suitability of detection of methylated, free-circulating DNA as a
response marker for patients with metastatic colorectal cancer.
In a different study, circulating KRAS G13D tumor DNA
(ctDNA) was used as an early marker for the response of patients
with metastatic colorectal cancers to treatment with oxaliplatin
or irinotecan (with or without bevacizumab). There, ctDNA lev-
els decreased in 41 of 48 patients and correlated with response to
therapy measured by radiologic staging, whereas no significant
changes in CEA levels were observed.48 In another study circu-
lating miR-126 was identified as a potential biomarker for
response to a therapy consisting of chemotherapy and bevacizu-
mab in 68 patients with mCRCs.49 Another group identified
a marker panel for circulating tumor cells in 50 RAS-BRAF
Table 3. Multivariate analysis regarding the overall survival (OS)
Parameter Value HR 95% CI p
HPP1 BS2 Positive vs. negative 2.08 (1.54–2.80) <0.0001
Mutation BRAF vs. wild-type 2.63 (1.58–4.38) 0.0002
RAS vs. wild-type 1.31 (0.96–1.78) 0.0889
Grading G31G4 vs. G11G2 1.85 (1.36–2.51) <0.0001
ECOG >0 vs. 0 1.53 (1.15–2.05) 0.0041
No. of metastatic sites >1 vs. 1 1.42 (1.05–1.92) 0.0211
Based on the calculation and comparison of AIC values for different Cox models (Supporting Information Table 5), we decided to use a Cox model
including clinical parameters and the HPP1 mfcDNA levels at BS2 to perform a multivariate analysis for OS. The corresponding hazard ratios (HR)
and confidence intervals (95% CI) of this model are presented for each parameter. p values indicate statistical significant differences between
values.
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wild-type mCRC patients and were able to identify patients that
did (not) respond to a therapy including cetuximab or panitu-
mumab.50 These studies are all characterized by a limited num-
ber of patient samples and retrospective data analysis. In
comparison, we studied a homogeneous collection of 467 mCRC
patients that have all been treated with a fluoropyrimidine, oxali-
platin and bevacizumab in a prospective clinical study. Based on
our results, detection of methylated, free-circulating HPP1 DNA
is a prognostic as well as a response biomarker for mCRC
patients. For this reason, HPP1 mfcDNA might become a bio-
marker that could be used for monitoring response to first-line
therapy and switching therapy protocols earlier than indicated
by radiological staging. However, this potential use needs to be
confirmed by prospective studies guiding therapy depending on
the response of the biomarker. Furthermore, a study is desirable
that tests the various above-mentioned biomarkers and poten-
tially other markers head-to-head. Interestingly, in our as well as
another study,48 CEA was not suitable as an early marker to indi-
cate a response to therapy.
Our study benefits from the prospective collection of samples,
the large number of available patient samples and the homogenous
treatment of the mCRC patients included. Nevertheless, the treat-
ment protocol only included patients receiving a fluoropyrimidine,
oxaliplatin and bevacizumab; other relevant chemotherapeutics or
biologicals, like irinotecan or anti-EGFR antibodies, have not been
included in this study. The patients included in this study were not
pretreated. Hence, results using samples from pretreated patients
might be different. Due to the implemented protocol, blood sam-
ples were only taken before and after the first administration of the
combination chemotherapy. Repeated blood sampling during the
chemotherapy was not performed. Therefore, we do not know
whether even earlier time points after the first administration of
the chemotherapy would be feasible for the analysis of HPP1
mfcDNA. In the current study, there is (apart from CEA) no
Figure 3. Response curves for second blood HPP1 mfcDNA and CEA levels. (a, b) Response curves were generated by receiver-operator-analysis
(ROC) analysis and the area under the curve (AUC) was determined to find out if HPP1 mfcDNA in the second blood sample discriminate between
CRC patients with “response or stable” (CR, PR, SD) versus “progressive” (PD) disease, respectively, according to the radiological staging 12 weeks
(a) or 24 weeks (b) after start of treatment. The sensitivity (“Sens.”), specificity (“Spez.”), positive predictive value (“PPV”) and negative predictive
value (“NPV”) are given for both analyses. (c, d) These ROC analyses were repeated for CEA levels in the second blood sample based on the
radiological staging 12 (c) or 24 weeks (d) after start of treatment. The AUC for each analysis is given in the upper left corner of the graph area.
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comparison with other biomarkers with potential clinical rele-
vance, like RAS mutational status or lactate dehydrogenase (LDH)
levels. However, we compared the suitability of HPP1 mfcDNA,
CEA and LDH as prognostic biomarkers in a previous study.42
Similarly, the correlation of the HPP1 methylation status in tumor
and blood samples of the same patients was not part of this study
but has been reported earlier by us.33
In conclusion, detection of HPP1 mfcDNA has the poten-
tial to become a clinically relevant biomarker. In CRC
patients with metastatic diseases, analysis of HPP1 mfcDNA
is a suitable prognostic biomarker. In addition, detection of
HPP1 mfcDNA could be used as a marker to monitor
response to therapy and help to identify mCRC patients who
most likely benefit from a combination therapy containing a
fluoropyrimidine, oxaliplatin and bevacizumab. However,
further studies are needed to establish the detection of HPP1
mfcDNA as a prognostic and response marker for clinical
use and to guide therapeutic decisions.
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